Skip to main content
Top
Published in: Journal of General Internal Medicine 8/2015

01-08-2015 | Original Research

Simulating Strategies for Improving Control of Hypertension Among Patients with Usual Source of Care in the United States: The Blood Pressure Control Model

Authors: Valy Fontil, MD, MAS, Kirsten Bibbins-Domingo, PhD, MD, MAS, Dhruv S. Kazi, MD, MSc, MS, Stephen Sidney, MD, MPH, Pamela G. Coxson, PhD, Raman Khanna, MD, MAS, Ronald G. Victor, MD, Mark J. Pletcher, MD, MPH

Published in: Journal of General Internal Medicine | Issue 8/2015

Login to get access

ABSTRACT

BACKGROUND

Only half of hypertensive adults achieve blood pressure (BP) control in the United States, and it is unclear how BP control rates may be improved most effectively and efficiently at the population level.

OBJECTIVE

We sought to compare the potential effects of system-wide isolated improvements in medication adherence, visit frequency, and higher physician prescription rate on achieving BP control at 52 weeks.

DESIGN

We developed a Markov microsimulation model of patient-level, physician-level, and system-level processes involved in controlling hypertension with medications. The model is informed by data from national surveys, cohort studies and trials, and was validated against two multicenter clinical trials (ALLHAT and VALUE).

SUBJECTS

We studied a simulated, nationally representative cohort of patients with diagnosed but uncontrolled hypertension with a usual source of care.

INTERVENTIONS

We simulated a base case and improvements of 10 and 50 %, and an ideal scenario for three modifiable parameters: visit frequency, treatment intensification, and medication adherence. Ideal scenarios were defined as 100 % for treatment intensification and adherence, and return visits occurring within 4 weeks of an elevated office systolic BP.

MAIN OUTCOME

BP control at 52 weeks of follow-up was examined.

RESULTS

Among 25,000 hypothetical adult patients with uncontrolled hypertension (systolic BP ≥ 140 mmHg), only 18 % achieved BP control after 52 weeks using base-case assumptions. With 10/50 %/idealized enhancements in each isolated parameter, enhanced treatment intensification achieved the greatest BP control (19/23/71 %), compared with enhanced visit frequency (19/21/35 %) and medication adherence (19/23/26 %). When all three processes were idealized, the model predicted a BP control rate of 95 % at 52 weeks.

CONCLUSION

Substantial improvements in BP control can only be achieved through major improvements in processes of care. Healthcare systems may achieve greater success by increasing the frequency of clinical encounters and improving physicians’ prescribing behavior than by attempting to improve patient adherence to medications.
Appendix
Available only for authorised users
Literature
1.
go back to reference Yang Q, Cogswell ME, Flanders WD, et al. Trends in cardiovascular health metrics and associations with all-cause and CVD mortality among US adults. JAMA. 2012;307(12):1273–83.PubMedCrossRef Yang Q, Cogswell ME, Flanders WD, et al. Trends in cardiovascular health metrics and associations with all-cause and CVD mortality among US adults. JAMA. 2012;307(12):1273–83.PubMedCrossRef
2.
go back to reference Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997;350(9080):757–64.PubMedCrossRef Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997;350(9080):757–64.PubMedCrossRef
3.
go back to reference Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887–98.PubMedCrossRef Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887–98.PubMedCrossRef
4.
go back to reference Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991;265(24):3255–3264. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991;265(24):3255–3264.
5.
go back to reference Landon BE, Hicks LS, O’Malley AJ, et al. Improving the management of chronic disease at community health centers. N Engl J Med. 2007;356(9):921–34.PubMedCrossRef Landon BE, Hicks LS, O’Malley AJ, et al. Improving the management of chronic disease at community health centers. N Engl J Med. 2007;356(9):921–34.PubMedCrossRef
6.
go back to reference Fung V, Huang J, Brand R, Newhouse JP, Hsu J. Hypertension treatment in a medicare population: adherence and systolic blood pressure control. Clin Ther. 2007;29(5):972–84.PubMedCrossRef Fung V, Huang J, Brand R, Newhouse JP, Hsu J. Hypertension treatment in a medicare population: adherence and systolic blood pressure control. Clin Ther. 2007;29(5):972–84.PubMedCrossRef
7.
go back to reference LaFleur J, Nelson RE, Sauer BC, Nebeker JR. Overestimation of the effects of adherence on outcomes: a case study in healthy user bias and hypertension. Heart. 2011;97(22):1862–9.PubMedCrossRef LaFleur J, Nelson RE, Sauer BC, Nebeker JR. Overestimation of the effects of adherence on outcomes: a case study in healthy user bias and hypertension. Heart. 2011;97(22):1862–9.PubMedCrossRef
8.
go back to reference Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008. JAMA. 2010;303(20):2043–50.PubMedCrossRef Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008. JAMA. 2010;303(20):2043–50.PubMedCrossRef
9.
go back to reference James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507–20.PubMedCrossRef James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507–20.PubMedCrossRef
10.
go back to reference Navar-Boggan AM, Pencina MJ, Williams K, Sniderman AD, Peterson ED. Proportion of US adults potentially affected by the 2014 hypertension guideline. JAMA. 2014;311(14):1424–9.PubMedCrossRef Navar-Boggan AM, Pencina MJ, Williams K, Sniderman AD, Peterson ED. Proportion of US adults potentially affected by the 2014 hypertension guideline. JAMA. 2014;311(14):1424–9.PubMedCrossRef
11.
go back to reference Glynn LG, Murphy AW, Smith SM, Schroeder K, Fahey T. Interventions used to improve control of blood pressure in patients with hypertension. Cochrane Database Syst Rev. 2010;3:CD005182.PubMed Glynn LG, Murphy AW, Smith SM, Schroeder K, Fahey T. Interventions used to improve control of blood pressure in patients with hypertension. Cochrane Database Syst Rev. 2010;3:CD005182.PubMed
12.
go back to reference Jaffe MG, Lee GA, Young JD, Sidney S, Go AS. Improved blood pressure control associated with a large-scale hypertension program. JAMA. 2013;310(7):699–705.PubMedCentralPubMedCrossRef Jaffe MG, Lee GA, Young JD, Sidney S, Go AS. Improved blood pressure control associated with a large-scale hypertension program. JAMA. 2013;310(7):699–705.PubMedCentralPubMedCrossRef
13.
go back to reference Fletcher RD, Amdur RL, Kolodner R, et al. Blood pressure control among US veterans: a large multiyear analysis of blood pressure data from the Veterans Administration health data repository. Circulation. 2012;125(20):2462–8.PubMedCrossRef Fletcher RD, Amdur RL, Kolodner R, et al. Blood pressure control among US veterans: a large multiyear analysis of blood pressure data from the Veterans Administration health data repository. Circulation. 2012;125(20):2462–8.PubMedCrossRef
15.
go back to reference Turchin A, Goldberg SI, Shubina M, Einbinder JS, Conlin PR. Encounter frequency and blood pressure in hypertensive patients with diabetes mellitus. Hypertension. 2010;56(1):68–74.PubMedCentralPubMedCrossRef Turchin A, Goldberg SI, Shubina M, Einbinder JS, Conlin PR. Encounter frequency and blood pressure in hypertensive patients with diabetes mellitus. Hypertension. 2010;56(1):68–74.PubMedCentralPubMedCrossRef
16.
go back to reference Mancia G, Facchetti R, Parati G, Zanchetti A. Visit-to-visit blood pressure variability, carotid atherosclerosis, and cardiovascular events in the European Lacidipine Study on Atherosclerosis. Circulation. 2012;126(5):569–78.PubMedCrossRef Mancia G, Facchetti R, Parati G, Zanchetti A. Visit-to-visit blood pressure variability, carotid atherosclerosis, and cardiovascular events in the European Lacidipine Study on Atherosclerosis. Circulation. 2012;126(5):569–78.PubMedCrossRef
17.
go back to reference Khanna RR, Victor RG, Bibbins-Domingo K, Shapiro MF, Pletcher MJ. Missed opportunities for treatment of uncontrolled hypertension at physician office visits in the United States, 2005 through 2009. Arch Intern Med. 2012;172(17):1344–5.PubMedCrossRef Khanna RR, Victor RG, Bibbins-Domingo K, Shapiro MF, Pletcher MJ. Missed opportunities for treatment of uncontrolled hypertension at physician office visits in the United States, 2005 through 2009. Arch Intern Med. 2012;172(17):1344–5.PubMedCrossRef
18.
go back to reference Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.PubMedCentralPubMedCrossRef Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.PubMedCentralPubMedCrossRef
19.
go back to reference Hill MN, Miller NH, DeGeest S. American Society of Hypertension Writing G. ASH position paper: Adherence and persistence with taking medication to control high blood pressure. J Clin Hypertens (Greenwich). 2010;12(10):757–64.CrossRef Hill MN, Miller NH, DeGeest S. American Society of Hypertension Writing G. ASH position paper: Adherence and persistence with taking medication to control high blood pressure. J Clin Hypertens (Greenwich). 2010;12(10):757–64.CrossRef
20.
go back to reference Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ. 2008;336(7653):1114–7.PubMedCentralPubMedCrossRef Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ. 2008;336(7653):1114–7.PubMedCentralPubMedCrossRef
21.
go back to reference Officers A, Coordinators for the ACRGTA, Lipid-Lowering Treatment to Prevent Heart Attack T. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981–2997. Officers A, Coordinators for the ACRGTA, Lipid-Lowering Treatment to Prevent Heart Attack T. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981–2997.
22.
go back to reference Julius S, Kjeldsen SE, Brunner H, et al. VALUE trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. Am J Hypertens. 2003;16(7):544–8.PubMedCrossRef Julius S, Kjeldsen SE, Brunner H, et al. VALUE trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. Am J Hypertens. 2003;16(7):544–8.PubMedCrossRef
23.
go back to reference Glied S, Tilipman N. Simulation modeling of health care policy. Annu Rev Public Health. 2010;31:439–55.PubMedCrossRef Glied S, Tilipman N. Simulation modeling of health care policy. Annu Rev Public Health. 2010;31:439–55.PubMedCrossRef
24.
go back to reference Weinstein MC, Toy EL, Sandberg EA, et al. Modeling for health care and other policy decisions: uses, roles, and validity. Value Health. 2001;4(5):348–61.PubMedCrossRef Weinstein MC, Toy EL, Sandberg EA, et al. Modeling for health care and other policy decisions: uses, roles, and validity. Value Health. 2001;4(5):348–61.PubMedCrossRef
25.
go back to reference Mandelblatt JS, Cronin KA, Bailey S, et al. Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med. 2009;151(10):738–47.PubMedCentralPubMedCrossRef Mandelblatt JS, Cronin KA, Bailey S, et al. Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med. 2009;151(10):738–47.PubMedCentralPubMedCrossRef
26.
go back to reference Kristensen AH, Flottemesch TJ, Maciosek MV, et al. Reducing Childhood Obesity through U.S. Federal Policy: A Microsimulation Analysis. Am J Prev Med. 2014. Kristensen AH, Flottemesch TJ, Maciosek MV, et al. Reducing Childhood Obesity through U.S. Federal Policy: A Microsimulation Analysis. Am J Prev Med. 2014.
27.
go back to reference Farley TA, Dalal MA, Mostashari F, Frieden TR. Deaths preventable in the U.S. by improvements in use of clinical preventive services. Am J Prev Med. 2010;38(6):600–9.PubMedCrossRef Farley TA, Dalal MA, Mostashari F, Frieden TR. Deaths preventable in the U.S. by improvements in use of clinical preventive services. Am J Prev Med. 2010;38(6):600–9.PubMedCrossRef
28.
go back to reference Turner MJ, van Schalkwyk JM. Blood pressure variability causes spurious identification of hypertension in clinical studies: a computer simulation study. Am J Hypertens. 2008;21(1):85–91.PubMedCrossRef Turner MJ, van Schalkwyk JM. Blood pressure variability causes spurious identification of hypertension in clinical studies: a computer simulation study. Am J Hypertens. 2008;21(1):85–91.PubMedCrossRef
29.
go back to reference Daugherty SL, Powers JD, Magid DJ, et al. The association between medication adherence and treatment intensification with blood pressure control in resistant hypertension. Hypertension. 2012;60(2):303–9.PubMedCentralPubMedCrossRef Daugherty SL, Powers JD, Magid DJ, et al. The association between medication adherence and treatment intensification with blood pressure control in resistant hypertension. Hypertension. 2012;60(2):303–9.PubMedCentralPubMedCrossRef
30.
go back to reference Rose AJ, Berlowitz DR, Manze M, Orner MB, Kressin NR. Intensifying therapy for hypertension despite suboptimal adherence. Hypertension. 2009;54(3):524–9.PubMedCentralPubMedCrossRef Rose AJ, Berlowitz DR, Manze M, Orner MB, Kressin NR. Intensifying therapy for hypertension despite suboptimal adherence. Hypertension. 2009;54(3):524–9.PubMedCentralPubMedCrossRef
31.
go back to reference Holder KK. Interventions to improve blood pressure control in patients with hypertension. Am Fam Physician. 2007;76(3):373–4.PubMed Holder KK. Interventions to improve blood pressure control in patients with hypertension. Am Fam Physician. 2007;76(3):373–4.PubMed
32.
go back to reference Fahey T, Schroeder K, Ebrahim S. Interventions used to improve control of blood pressure in patients with hypertension. Cochrane Database Syst Rev. 2006;2:CD005182.PubMed Fahey T, Schroeder K, Ebrahim S. Interventions used to improve control of blood pressure in patients with hypertension. Cochrane Database Syst Rev. 2006;2:CD005182.PubMed
33.
go back to reference Frieden TR, King SM, Wright JS. Protocol-based treatment of hypertension: a critical step on the pathway to progress. JAMA. 2014;311(1):21–2.PubMedCrossRef Frieden TR, King SM, Wright JS. Protocol-based treatment of hypertension: a critical step on the pathway to progress. JAMA. 2014;311(1):21–2.PubMedCrossRef
34.
go back to reference Okonofua EC, Simpson KN, Jesri A, Rehman SU, Durkalski VL, Egan BM. Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hypertension. 2006;47(3):345–51.PubMedCrossRef Okonofua EC, Simpson KN, Jesri A, Rehman SU, Durkalski VL, Egan BM. Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hypertension. 2006;47(3):345–51.PubMedCrossRef
35.
go back to reference Berlowitz DR, Ash AS, Hickey EC, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med. 1998;339(27):1957–63.PubMedCrossRef Berlowitz DR, Ash AS, Hickey EC, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med. 1998;339(27):1957–63.PubMedCrossRef
36.
37.
go back to reference Fontil V, Pletcher M, Khanna R, Guzman D, Victor R, Bibbins-Domingo K. Physician Underutilization of Effective Medications for Resistant Hypertension at Office Visits in the United States: NAMCS 2006–2010. Journal of General Internal Medicine. 2013:1–9. Fontil V, Pletcher M, Khanna R, Guzman D, Victor R, Bibbins-Domingo K. Physician Underutilization of Effective Medications for Resistant Hypertension at Office Visits in the United States: NAMCS 2006–2010. Journal of General Internal Medicine. 2013:1–9.
38.
go back to reference Davis BR, Ford CE, Remington RD, Stamler R, Hawkins CM. The Hypertension Detection and Follow-up Program design, methods, and baseline characteristics and blood pressure response of the study population. Prog Cardiovasc Dis. 1986;29(3 Suppl 1):11–28.PubMedCrossRef Davis BR, Ford CE, Remington RD, Stamler R, Hawkins CM. The Hypertension Detection and Follow-up Program design, methods, and baseline characteristics and blood pressure response of the study population. Prog Cardiovasc Dis. 1986;29(3 Suppl 1):11–28.PubMedCrossRef
39.
go back to reference Selby JV, Uratsu CS, Fireman B, et al. Treatment intensification and risk factor control: toward more clinically relevant quality measures. Med Care. 2009;47(4):395–402.PubMedCentralPubMedCrossRef Selby JV, Uratsu CS, Fireman B, et al. Treatment intensification and risk factor control: toward more clinically relevant quality measures. Med Care. 2009;47(4):395–402.PubMedCentralPubMedCrossRef
40.
go back to reference Stewart S, Carrington MJ, Swemmer CH, et al. Effect of intensive structured care on individual blood pressure targets in primary care: multicentre randomised controlled trial. BMJ. 2012;345:e7156.PubMedCentralPubMedCrossRef Stewart S, Carrington MJ, Swemmer CH, et al. Effect of intensive structured care on individual blood pressure targets in primary care: multicentre randomised controlled trial. BMJ. 2012;345:e7156.PubMedCentralPubMedCrossRef
41.
go back to reference Magid DJ, Ho PM, Olson KL, et al. A multimodal blood pressure control intervention in 3 healthcare systems. Am J Manag Care. 2011;17(4):e96–103.PubMed Magid DJ, Ho PM, Olson KL, et al. A multimodal blood pressure control intervention in 3 healthcare systems. Am J Manag Care. 2011;17(4):e96–103.PubMed
42.
go back to reference Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560–72.PubMedCrossRef Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560–72.PubMedCrossRef
43.
go back to reference Guthmann R, Davis N, Brown M, Elizondo J. Visit frequency and hypertension. J Clin Hypertens (Greenwich). 2005;7(6):327–32.CrossRef Guthmann R, Davis N, Brown M, Elizondo J. Visit frequency and hypertension. J Clin Hypertens (Greenwich). 2005;7(6):327–32.CrossRef
44.
go back to reference Clark CE, Smith LF, Taylor RS, Campbell JL. Nurse led interventions to improve control of blood pressure in people with hypertension: systematic review and meta-analysis. BMJ. 2010;341:c3995.PubMedCentralPubMedCrossRef Clark CE, Smith LF, Taylor RS, Campbell JL. Nurse led interventions to improve control of blood pressure in people with hypertension: systematic review and meta-analysis. BMJ. 2010;341:c3995.PubMedCentralPubMedCrossRef
45.
go back to reference Morgado MP, Morgado SR, Mendes LC, Pereira LJ, Castelo-Branco M. Pharmacist interventions to enhance blood pressure control and adherence to antihypertensive therapy: Review and meta-analysis. Am J Health Syst Pharm. 2011;68(3):241–53.PubMedCrossRef Morgado MP, Morgado SR, Mendes LC, Pereira LJ, Castelo-Branco M. Pharmacist interventions to enhance blood pressure control and adherence to antihypertensive therapy: Review and meta-analysis. Am J Health Syst Pharm. 2011;68(3):241–53.PubMedCrossRef
46.
go back to reference Rader F, Elashoff RM, Niknezhad S, Victor RG. Differential treatment of hypertension by primary care providers and hypertension specialists in a barber-based intervention trial to control hypertension in Black men. Am J Cardiol. 2013;112(9):1421–6.PubMedCentralPubMedCrossRef Rader F, Elashoff RM, Niknezhad S, Victor RG. Differential treatment of hypertension by primary care providers and hypertension specialists in a barber-based intervention trial to control hypertension in Black men. Am J Cardiol. 2013;112(9):1421–6.PubMedCentralPubMedCrossRef
47.
go back to reference Vigen R, Shetterly S, Magid DJ, et al. A comparison between antihypertensive medication adherence and treatment intensification as potential clinical performance measures. Circ Cardiovasc Qual Outcomes. 2012;5(3):276–82.PubMedCrossRef Vigen R, Shetterly S, Magid DJ, et al. A comparison between antihypertensive medication adherence and treatment intensification as potential clinical performance measures. Circ Cardiovasc Qual Outcomes. 2012;5(3):276–82.PubMedCrossRef
48.
go back to reference Manze M, Rose AJ, Orner MB, Berlowitz DR, Kressin NR. Understanding racial disparities in treatment intensification for hypertension management. J Gen Intern Med. 2010;25(8):819–25.PubMedCentralPubMedCrossRef Manze M, Rose AJ, Orner MB, Berlowitz DR, Kressin NR. Understanding racial disparities in treatment intensification for hypertension management. J Gen Intern Med. 2010;25(8):819–25.PubMedCentralPubMedCrossRef
49.
go back to reference Franklin SS, Larson MG, Khan SA, et al. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation. 2001;103(9):1245–9.PubMedCrossRef Franklin SS, Larson MG, Khan SA, et al. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation. 2001;103(9):1245–9.PubMedCrossRef
50.
go back to reference Patel NC, Crismon ML, Miller AL, Johnsrud MT. Drug adherence: effects of decreased visit frequency on adherence to clozapine therapy. Pharmacotherapy. 2005;25(9):1242–7.PubMedCrossRef Patel NC, Crismon ML, Miller AL, Johnsrud MT. Drug adherence: effects of decreased visit frequency on adherence to clozapine therapy. Pharmacotherapy. 2005;25(9):1242–7.PubMedCrossRef
51.
go back to reference Hypertension EETFftMoA. 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens. 2013;31(10):1925–38.CrossRef Hypertension EETFftMoA. 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens. 2013;31(10):1925–38.CrossRef
Metadata
Title
Simulating Strategies for Improving Control of Hypertension Among Patients with Usual Source of Care in the United States: The Blood Pressure Control Model
Authors
Valy Fontil, MD, MAS
Kirsten Bibbins-Domingo, PhD, MD, MAS
Dhruv S. Kazi, MD, MSc, MS
Stephen Sidney, MD, MPH
Pamela G. Coxson, PhD
Raman Khanna, MD, MAS
Ronald G. Victor, MD
Mark J. Pletcher, MD, MPH
Publication date
01-08-2015
Publisher
Springer US
Published in
Journal of General Internal Medicine / Issue 8/2015
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-015-3231-8

Other articles of this Issue 8/2015

Journal of General Internal Medicine 8/2015 Go to the issue

Healing Arts: Materia Medica

The Journey

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.